SMT202400193T1 - Nuovi metodi per bersagliare cellule staminali cancerose - Google Patents

Nuovi metodi per bersagliare cellule staminali cancerose

Info

Publication number
SMT202400193T1
SMT202400193T1 SM20240193T SMT202400193T SMT202400193T1 SM T202400193 T1 SMT202400193 T1 SM T202400193T1 SM 20240193 T SM20240193 T SM 20240193T SM T202400193 T SMT202400193 T SM T202400193T SM T202400193 T1 SMT202400193 T1 SM T202400193T1
Authority
SM
San Marino
Prior art keywords
stem cells
cancer stem
novel methods
targeting cancer
targeting
Prior art date
Application number
SM20240193T
Other languages
English (en)
Italian (it)
Inventor
Wei Li
Chiang Jia Li
David Leggett
Youzhi Li
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of SMT202400193T1 publication Critical patent/SMT202400193T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SM20240193T 2010-03-19 2011-03-21 Nuovi metodi per bersagliare cellule staminali cancerose SMT202400193T1 (it)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31589010P 2010-03-19 2010-03-19
US31588610P 2010-03-19 2010-03-19
US32581410P 2010-04-19 2010-04-19
EP11757135.6A EP2547205B1 (en) 2010-03-19 2011-03-21 Novel methods for targeting cancer stem cells
PCT/US2011/029283 WO2011116399A1 (en) 2010-03-19 2011-03-21 Novel methods for targeting cancer stem cells

Publications (1)

Publication Number Publication Date
SMT202400193T1 true SMT202400193T1 (it) 2024-07-09

Family

ID=47678420

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20240193T SMT202400193T1 (it) 2010-03-19 2011-03-21 Nuovi metodi per bersagliare cellule staminali cancerose

Country Status (18)

Country Link
US (2) US9730909B2 (https=)
EP (1) EP2547205B1 (https=)
JP (1) JP2013522326A (https=)
CN (1) CN103025159A (https=)
AU (1) AU2011227023B2 (https=)
BR (1) BR112012023660B8 (https=)
CA (2) CA2793527A1 (https=)
DK (1) DK2547205T3 (https=)
ES (1) ES2987670T3 (https=)
FI (1) FI2547205T3 (https=)
HR (1) HRP20240658T1 (https=)
LT (1) LT2547205T (https=)
PL (1) PL2547205T3 (https=)
RS (1) RS65536B1 (https=)
RU (1) RU2591823C2 (https=)
SI (1) SI2547205T1 (https=)
SM (1) SMT202400193T1 (https=)
WO (1) WO2011116399A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
RU2657750C1 (ru) * 2010-03-19 2018-06-15 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
WO2015120304A1 (en) 2014-02-07 2015-08-13 Boston Biomedical, Inc. 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
CA2951627A1 (en) 2014-06-09 2015-12-17 Kyoto Pharmaceutical Industries, Ltd. Naphthofuran derivatives as anticancer agent
JP2018511645A (ja) 2015-04-17 2018-04-26 ボストン バイオメディカル, インコーポレイテッド 癌を治療するための方法
JP2018511643A (ja) 2015-04-17 2018-04-26 ボストン バイオメディカル, インコーポレイテッド 癌を治療するための方法
TW201717935A (zh) 2015-06-03 2017-06-01 波士頓生醫公司 用於治療癌症的組成物和方法
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
EP3405189A1 (en) 2016-01-20 2018-11-28 Boston Biomedical, Inc. Methods for treating cancer
WO2018005444A2 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3762391A4 (en) * 2018-03-08 2022-08-03 ExxonMobil Technology and Engineering Company SPIROCENTRIC COMPOUNDS AND POLYMERS THEREOF
JP7513286B2 (ja) 2018-10-12 2024-07-09 1グローブ バイオメディカル カンパニー, リミテッド 化学療法難治性がんの治療のための新しい併用薬方法
CN111825644B (zh) * 2019-04-18 2023-07-28 中国医学科学院药物研究所 2,3-二氢萘并[2,3-b]呋喃-4,9-二酮类化合物及其制备方法和用途
CN117350965A (zh) * 2023-10-07 2024-01-05 中国原子能科学研究院 对象内放射性微球的指标预估装置

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
EP1146869A2 (en) 1999-01-27 2001-10-24 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
MXPA02000828A (es) 1999-08-02 2002-07-30 Hoffmann La Roche Nuevos antagonistas retinoiides selectivos.
JP2001097860A (ja) * 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
WO2002078617A2 (en) 2001-03-28 2002-10-10 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
WO2003045357A1 (en) 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP1990055A3 (en) * 2001-11-29 2011-11-16 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
AU2003215524A1 (en) 2002-03-15 2003-09-29 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
US20060142271A1 (en) * 2002-09-17 2006-06-29 Klaus Muller Novel lapacho compounds and methods of use thereof
TWI335913B (en) * 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
MXPA06006460A (es) 2003-12-11 2006-08-23 Univ Texas Compuestos para el tratamiento de enfermedades proliferativas celulares.
WO2005110477A2 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
CA2599393A1 (en) 2005-02-25 2006-08-31 The Regents Of The University Of Michigan Small molecule inhibitors of stat3 and the uses thereof
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
CN101142202A (zh) * 2005-03-16 2008-03-12 太日保日本株式会社 抗癌化合物及其中间体和生产方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2007100640A2 (en) 2006-02-21 2007-09-07 The Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
RU2456265C2 (ru) 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US8828451B2 (en) 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性2−(1−ヒドロキシエチル)−5−ヒドロキシナフト[2,3−b]フラン−4,9−ジオンの製法
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
US20100298402A1 (en) 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
RU2657750C1 (ru) * 2010-03-19 2018-06-15 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки

Also Published As

Publication number Publication date
EP2547205B1 (en) 2024-03-20
JP2013522326A (ja) 2013-06-13
HRP20240658T1 (hr) 2024-08-16
BR112012023660B1 (pt) 2021-05-18
WO2011116399A1 (en) 2011-09-22
US20130028944A1 (en) 2013-01-31
US20170319537A1 (en) 2017-11-09
AU2011227023A1 (en) 2012-09-27
US9730909B2 (en) 2017-08-15
BR112012023660A2 (pt) 2015-09-15
LT2547205T (lt) 2024-06-10
RU2591823C2 (ru) 2016-07-20
CA2946890A1 (en) 2011-09-22
PL2547205T3 (pl) 2024-07-08
DK2547205T3 (da) 2024-05-27
FI2547205T3 (fi) 2024-05-27
RS65536B1 (sr) 2024-06-28
EP2547205A1 (en) 2013-01-23
ES2987670T3 (es) 2024-11-15
SI2547205T1 (sl) 2024-08-30
EP2547205A4 (en) 2013-08-14
RU2012144420A (ru) 2014-04-27
AU2011227023B2 (en) 2015-05-28
BR112012023660B8 (pt) 2021-05-25
CN103025159A (zh) 2013-04-03
CA2793527A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
LT2547205T (lt) Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai
IL220756A0 (en) Herbicide-tolerant plants
IL225635A0 (en) Supplement for cell culture
PT2785834T (pt) Composição de células estaminais melhorada
HUE066482T2 (hu) Új eljárások rákõssejtek megcélzására
EP2601290A4 (en) SOMATIC STEM CELLS
EP2772268B8 (en) Cancer stem cell-specific molecule
GB201016139D0 (en) Cancer phosholipidome
IL255309A0 (en) Reprogramming of cancer cells
PL2547766T3 (pl) Rośliny tolerancyjne względem herbicydów
EP2760996A4 (en) SOMATIC STEM CELLS
GB201012590D0 (en) Methods for diagnosing cancer
WO2011116344A9 (en) Targeting cancer stem cells
EP2533789A4 (en) METHOD FOR IMPROVING THE FUNCTIONALITY OF SPERM
GB201007944D0 (en) Methods
SMT202100545T1 (it) Vaccini contro il cancro mirati alle cellule staminali cancerose
PL2568796T3 (pl) Półzawieszany pług obracalny
WO2012106368A9 (en) Methods for inhibiting prostate cancer
GB201011367D0 (en) Methods
CY1126935T1 (el) Νεες μεθοδοι για την στοχευση καρκινικων βλαστοκυτταρων
SG196714A1 (en) Cancer stem cell inhibition
GB201021372D0 (en) CD24 cancer stem cell
ZA201205860B (en) Herbicide-tolerant plants
AU2011900981A0 (en) Inhibition of cancer stem cells
GB201012495D0 (en) Targeted differntiation of stem cells